Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

By Any Means Necessary - Public Citizen

Judge asks if Allergan's patent deal with Mohawk tribe is a 'sham

Allergan's Mohawk Tribe Patent Defense Is Eyewash - Court

Prescription Drug Costs

AbbVie and Allergan's Merger Hopes to Be a Humira Dodge - Bloomberg

Allergan CEO Defends Mohawk Tribe Restasis Patent Deal

Prescription Drug Costs

Page 67 – Business North Carolina

CQ Researcher - Prescription Drug Costs

Speaker Bios Do Not Delete - Foundry Events

Allergan does patent deal for Restasis with Native American tribe

Prescription Drug Costs

Senators blast Allergan's tribal deal, social contract as 'hypocrisy

Allergan Restasis Patents Invalid in Texas District Court

BLS Letter To Grassley Feinstein 10-3-17 FINAL, PDF, Intellectual Property